当前位置:首页 - 行情中心 - 昭衍新药(603127) - 财务分析 - 现金流量表

昭衍新药

(603127)

  

流通市值:251.65亿  总市值:300.41亿
流通股本:6.28亿   总股本:7.49亿

现金流量表

报告期2026-09-302026-06-302026-03-312025-12-31
公司类型通用通用通用通用
一、经营活动产生的现金流量:
  销售商品、提供劳务收到的现金2,024,790,617.431,240,212,877.88548,028,113.11,772,381,774.15
  收到的税费返还3,033,908.861,872,280.83975,507.757,291,392.16
  收到其他与经营活动有关的现金20,211,286.614,419,854.357,844,283.1952,454,155.54
  经营活动现金流入小计2,048,035,812.891,256,505,013.06556,847,904.041,832,127,321.85
  购买商品、接受劳务支付的现金536,533,168.27358,573,410.34181,582,001.45567,303,820.73
  支付给职工以及为职工支付的现金521,658,821.78357,398,095.63207,289,895.12658,177,529.56
  支付的各项税费75,895,570.5843,523,614.1822,622,089.9363,156,061.17
  支付其他与经营活动有关的现金60,666,329.4339,795,994.0517,742,754.4698,923,188.26
  经营活动现金流出小计1,194,753,890.06799,291,114.2429,236,740.961,387,560,599.72
  经营活动产生的现金流量净额853,281,922.83457,213,898.86127,611,163.08444,566,722.13
二、投资活动产生的现金流量:
  收回投资收到的现金3,304,862,960.62,459,572,001.691,415,062,758.672,276,223,325.91
  取得投资收益收到的现金57,846,621.2346,010,480.0522,020,747.9575,133,433.24
  处置固定资产、无形资产和其他长期资产收回的现金净额26,85816,81813,2501,361,360.16
  收到的其他与投资活动有关的现金---17,793,632.08
  投资活动现金流入小计3,362,736,439.832,505,599,299.741,437,096,756.622,370,511,751.39
  购建固定资产、无形资产和其他长期资产支付的现金430,767,764.3401,373,968.13369,283,452.94143,602,144.53
  投资支付的现金4,091,346,277.782,596,690,277.781,110,000,0002,646,102,552.69
  投资活动现金流出小计4,522,114,042.082,998,064,245.911,479,283,452.942,789,704,697.22
  投资活动产生的现金流量净额-1,159,377,602.25-492,464,946.17-42,186,696.32-419,192,945.83
三、筹资活动产生的现金流量:
  吸收投资收到的现金50,221,51550,221,515--
  筹资活动现金流入平衡项目00--
  筹资活动现金流入小计50,221,51550,221,515--
  分配股利、利润或偿付利息支付的现金89,563,433.4975,261,491.28-22,385,229
  支付其他与筹资活动有关的现金15,263,740.4610,586,143.365,447,459.8244,598,826.31
  筹资活动现金流出小计104,827,173.9585,847,634.645,447,459.8266,984,055.31
  筹资活动产生的现金流量净额-54,605,658.95-35,626,119.64-5,447,459.82-66,984,055.31
四、汇率变动对现金及现金等价物的影响-20,369,798.4-17,041,736.06-8,746,427.18-11,738,509.02
五、现金及现金等价物净增加额-381,071,136.77-87,918,903.0171,230,579.76-53,348,788.03
  加:期初现金及现金等价物余额911,854,340.56911,854,340.56911,854,340.56965,203,128.59
  期末现金及现金等价物余额530,783,203.79823,935,437.55983,084,920.32911,854,340.56
补充资料:
  净利润-747,518,791.03-297,842,526.3
  资产减值准备-20,145,063.73-156,760,636.98
  固定资产和投资性房地产折旧-45,879,734.93-94,903,390.14
  其中:固定资产折旧、油气资产折耗、生产性生物资产折旧-45,879,734.93-94,903,390.14
  无形资产摊销-8,297,830.24-17,422,245.12
  长期待摊费用摊销-9,025,871.67-19,269,954.04
  递延收益摊销--4,693,668.89-4,818,186.92
  处置固定资产、无形资产和其他长期资产的损失----413,517.67
  固定资产报废损失-300,589.48-461,919.3
  公允价值变动损失--838,035,702.05--447,560,334.54
  财务费用--15,425,543.29--53,994,754.17
  投资损失--5,584,385.22--18,013,906.02
  递延所得税-47,475,091.52-119,241.75
  其中:递延所得税资产减少-3,899,055.52--6,320,664.55
    递延所得税负债增加-43,576,036-6,439,906.3
  存货的减少-2,049,142.06-214,517,124.57
  经营性应收项目的减少-20,172,179.83-62,295,986.6
  经营性应付项目的增加-396,399,386.59-68,228,112.06
  现金的期末余额-823,935,437.55-911,854,340.56
  减:现金的期初余额-911,854,340.56-965,203,128.59
  现金及现金等价物的净增加额--87,918,903.01--53,348,788.03
公告日期2026-10-292026-08-292026-04-302026-03-31
审计意见(境内)标准无保留意见
TOP↑